3,273 reports of this reaction
1.8% of all DIAZEPAM ORAL SOLUTION (CONCENTRATE) reports
#9 most reported adverse reaction
OFF LABEL USE is the #9 most commonly reported adverse reaction for DIAZEPAM ORAL SOLUTION (CONCENTRATE), manufactured by Alembic Pharmaceuticals Inc.. There are 3,273 FDA adverse event reports linking DIAZEPAM ORAL SOLUTION (CONCENTRATE) to OFF LABEL USE. This represents approximately 1.8% of all 177,526 adverse event reports for this drug.
Patients taking DIAZEPAM ORAL SOLUTION (CONCENTRATE) who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for DIAZEPAM ORAL SOLUTION (CONCENTRATE), but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for DIAZEPAM ORAL SOLUTION (CONCENTRATE):
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 3,273 FDA reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE). This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 1.8% of all adverse event reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE), making it a notable side effect.
If you experience off label use while taking DIAZEPAM ORAL SOLUTION (CONCENTRATE), contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.